Clinical Trial Update: Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

A Phase 3 study comparing cemiplimab (REGN2810) to platinum-based chemotherapy in metastatic non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cemiplimab (REGN2810) (cemiplimab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Carcinoma，Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell | Phase 3 | Status: COMPLETED